BMS's Opdivo/Yervoy combo improves OS in first-line RCC

Bristol-Myers Squibb Co. (NYSE:BMY) said a planned interim analysis of the Phase III CheckMate -214 trial showed that Opdivo nivolumab plus Yervoy ipilimumab as first-line treatment of renal cell carcinoma met the co-primary endpoint of improving overall survival (OS) compared to Sutent sunitinib in intermediate- and poor-risk patients. The combination also met the secondary endpoint of improving OS vs. Sutent among all randomized patients with untreated advanced or metastatic RCC. Based on the data, an IDMC recommended stopping the trial early.

Data will be presented at the European Society for Medical Oncology meeting in Madrid later this week...